AMD-070
AMD-070 Uses, Dosage, Side Effects, Food Interaction and all others data.
AMD-070 is a small molecule drug candidate that belongs to a new investigational class of anti-HIV drugs known as entry (fusion) inhibitors. Currently there is only one FDA-approved entry inhibitor, enfuvirtide (Fuzeon), that is available for the treatment of HIV infection. Several experimental entry inhibitors are now in early stage testing, including AMD-070, which targets the CXCR4 receptor on HIV and prevents the virus from entering and infecting healthy cells. Other entry inhibitors target the CCR5 receptor of HIV.These new agents are widely viewed as next generation anti-HIV drugs with the potential to significantly advance HIV therapeutics.
AMD-070 is a small molecule drug candidate that belongs to a new investigational class of anti-HIV drugs known as entry (fusion) inhibitors. Approximately 76% of HIV-patients with measurable viral load are infected with a strain of virus that is resistant to one or more classes of antiretroviral agents, thus reducing treatment options. Unlike many existing HIV drugs that target the virus after it has infected a healthy cell, AMD-070 blocks the virus from entering a healthy cell, thus preventing the replication process. AMD-070 targets the CXCR4 receptor on HIV and prevents the virus from entering and infecting healthy cells.* AMD-070 is specific for the CXCR4 receptor and does not interact with any other chemokine receptors in vitro* AMD-070 strongly inhibits viral infection by all CXCR4 using virus (including virus using CXCR4 alone and/or virus using CXCR4 and CCR5) in vitro* AMD-070 is orally bioavailable in animals* Suitable PK and toxicity profile for oral dosing* AMD-070 shows additive or synergistic effects in vitro in combination with other known anti-HIV agents* AMD-070 is active against CXCR4 using HIV strains that are resistant to existing antiretroviral therapies in vitro* Potent anti-HIV activity against CXCR4-using laboratory strains and clinical isolates
| Trade Name | AMD-070 |
| Generic | AMD-070 |
| Type | |
| Formula | C21H27N5 |
| Weight | Average: 349.482 Monoisotopic: 349.226645889 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in HIV infection.
How AMD-070 works
Chemokine receptors expressed on the surface of immune cells are known to play a critical role in virus infection and transmission. CXCR4, and another chemokine receptor CCR5, are involved in HIV infection.
The process of HIV entry begins with binding of the viral envelope glycoprotein to both the CD4 receptor and one of only two chemokine receptors, and ends with fusion of viral and cell membranes. Viral entry provides novel therapeutic targets against HIV. To date, at least 3 sub classes of HIV viral entry/fusion inhibitors have emerged:
- CD4 binding or attachment - targets initial recognition and binding of the viral glycoprotein gp120 to the cell-surface CD4 antigen.
- Chemokine co-receptor binding - targets binding of virus to the CCR5 or CXCR4 co-receptor.
- Fusion Inhibition - targets the viral glycoprotein gp41 inhibiting the fusion of virus with the cell.
Different strains of HIV prefer one receptor or the other, or may use either receptor to infect cells.
* 35% of strains use both CXCR4 and CCR5
* 5% of strains are pure CXCR4 using
* 60% of strains are pure CCR5 using
* An infected individual may harbor different levels of both CXCR4 and CCR5 using virus
* CXCR4 using virus independently predicts CD4 decline and HIV clinical progression and is associated with earlier mortality
Innovators Monograph
You find simplified version here AMD-070
